Cara Therapeutics is a biopharmaceutical company that develops and commercializes chemical entities targeting pruritus and pain by selectively targeting kappa opioid receptors. Its lead product is KORSUVA injection for the treatment of pruritus associated with chronic kidney disease. The company is also developing Oral KORSUVA for various pruritus indications and has license agreements with Maruishi Pharmaceutical and Chong Kun Dang Pharmaceutical for drug products containing difelikefalin in Japan and South Korea, respectively.